{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:39:50Z","timestamp":1791322790989,"version":"4.3.1"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T00:00:00Z","timestamp":1729728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-02434"],"award-info":[{"award-number":["2020-02434"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003792","name":"Hj\u00e4rnfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Treatment strategies that are efficient against established Alzheimer\u2019s disease (AD) are needed. BRICHOS is a molecular chaperone domain that prevents amyloid fibril formation and associated cellular toxicity. In this study, we treated an AD mouse model seven months after pathology onset, using intravenous administration of recombinant human (rh) Bri2 BRICHOS R221E. Two injections of rh Bri2 BRICHOS R221E per week for three months in AD mice reduced amyloid \u03b2 (A\u03b2) burden, and mitigated astro- and microgliosis, as determined by glial fibrillary acidic protein (GFAP) and ionized calcium-binding adaptor molecule 1 (Iba1) immunohistochemistry. Sequencing of RNA from cortical microglia cells showed that BRICHOS treatment normalized the expression of identified plaque-induced genes in mice and humans, including clusterin and GFAP. Rh Bri2 BRICHOS R221E passed the blood\u2013brain barrier (BBB) in age-matched wild-type mice as efficiently as in the AD mice, but then had no effect on measures of AD-like pathology, and mainly affected the expression of genes that affect cellular shape and movement. These results indicate a potential of rh Bri2 BRICHOS against advanced AD and underscore the ability of BRICHOS to target amyloid-induced pathology.<\/jats:p>","DOI":"10.1038\/s41398-024-03161-x","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T14:03:40Z","timestamp":1729778620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Intravenous chaperone treatment of late-stage Alzheimer\u00b4s disease (AD) mouse model affects amyloid plaque load, reactive gliosis and AD-related genes"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2140-0350","authenticated-orcid":false,"given":"Ruixin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Ohshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9755-6570","authenticated-orcid":false,"given":"Antonin","family":"Moranc\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8314-0927","authenticated-orcid":false,"given":"Marianne","family":"Schultzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5543-5963","authenticated-orcid":false,"given":"Gefei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8719-4703","authenticated-orcid":false,"given":"Jan","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,24]]},"reference":[{"key":"3161_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","volume":"15","author":"B Winblad","year":"2016","unstructured":"Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society. Lancet Neurol. 2016;15:455\u2013532.","journal-title":"Lancet Neurol"},{"key":"3161_CR2","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","volume":"21","author":"E Karran","year":"2022","unstructured":"Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21:306\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"3161_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327.","journal-title":"JAMA"},{"key":"3161_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"3161_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J, Chiao P, Bussiere T, Weinreb PH, Williams L, Maier M, et al. The antibody aducanumab reduces abeta plaques in Alzheimer\u2019s disease. Nature. 2016;537:50\u20136.","journal-title":"Nature"},{"key":"3161_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"3161_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-biochem-061516-045115","volume":"86","author":"F Chiti","year":"2017","unstructured":"Chiti F, Dobson CM. Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade. Annu Rev Biochem. 2017;86:27\u201368.","journal-title":"Annu Rev Biochem"},{"key":"3161_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","volume":"377","author":"C Ballard","year":"2011","unstructured":"Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer\u2019s disease. Lancet. 2011;377:1019\u201331.","journal-title":"Lancet"},{"key":"3161_CR9","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJHJ Selkoe","year":"2016","unstructured":"Selkoe DJHJ. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8:595\u2013608.","journal-title":"EMBO Mol Med"},{"key":"3161_CR10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nrn3880","volume":"16","author":"FL Heppner","year":"2015","unstructured":"Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16:358\u201372.","journal-title":"Nat Rev Neurosci"},{"key":"3161_CR11","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s42003-022-03169-3","volume":"5","author":"C Emre","year":"2022","unstructured":"Emre C, Arroyo-Garc\u00eda LE, Do KV, Jun B, Ohshima M, Alcalde SG, et al. Intranasal delivery of pro-resolving lipid mediators rescues memory and gamma oscillation impairment in AppNL-G-F\/NL-G-F mice. Commun Biol. 2022;5:245.","journal-title":"Commun Biol"},{"key":"3161_CR12","first-page":"235","volume":"19","author":"MR Wilson","year":"2023","unstructured":"Wilson MR, Satapathy S, Vendruscolo M. Extracellular protein homeostasis in neurodegenerative diseases. Nat Rev Neurol. 2023;19:235\u201345.","journal-title":"Nat Rev Neurol"},{"key":"3161_CR13","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0968-0004(02)02134-5","volume":"27","author":"L Sanchez-Pulido","year":"2002","unstructured":"Sanchez-Pulido L, Devos D, Valencia A. BRICHOS: a conserved domain in proteins associated with dementia, respiratory distress and cancer. Trends Biochem Sci. 2002;27:329\u201332.","journal-title":"Trends Biochem Sci"},{"key":"3161_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-2-180","volume":"2","author":"J Hedlund","year":"2009","unstructured":"Hedlund J, Johansson J, Persson B. BRICHOS\u2014a superfamily of multidomain proteins with diverse functions. BMC Res Notes. 2009;2:180.","journal-title":"BMC Res Notes"},{"key":"3161_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4645","volume":"32","author":"A Leppert","year":"2023","unstructured":"Leppert A, Poska H, Landreh M, Abelein A, Chen G, Johansson J. A new kid in the folding funnel: molecular chaperone activities of the BRICHOS domain. Protein Sci. 2023;32:e4645.","journal-title":"Protein Sci"},{"key":"3161_CR16","doi-asserted-by":"publisher","first-page":"E2752","DOI":"10.1073\/pnas.1715951115","volume":"115","author":"ME Oskarsson","year":"2018","unstructured":"Oskarsson ME, Hermansson E, Wang Y, Welsh N, Presto J, Johansson J, et al. BRICHOS domain of Bri2 inhibits islet amyloid polypeptide (IAPP) fibril formation and toxicity in human beta cells. Proc Natl Acad Sci USA. 2018;115:E2752\u2013E2761.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3161_CR17","doi-asserted-by":"publisher","first-page":"31608","DOI":"10.1074\/jbc.M112.393157","volume":"287","author":"H Willander","year":"2012","unstructured":"Willander H, Presto J, Askarieh G, Biverstal H, Frohm B, Knight SD, et al. BRICHOS domains efficiently delay fibrillation of amyloid beta-peptide. J Biol Chem. 2012;287:31608\u201317.","journal-title":"J Biol Chem"},{"key":"3161_CR18","doi-asserted-by":"publisher","first-page":"6807","DOI":"10.1007\/s00018-021-03932-5","volume":"78","author":"F Martins","year":"2021","unstructured":"Martins F, Santos I, Da Cruz OAB, Tambaro S, Rebelo S. The role of the integral type II transmembrane protein BRI2 in health and disease. Cell Mol Life Sci. 2021;78:6807\u201322.","journal-title":"Cell Mol Life Sci"},{"key":"3161_CR19","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1016\/j.neurobiolaging.2014.01.007","volume":"35","author":"M Del Campo","year":"2014","unstructured":"Del Campo M, Hoozemans JJ, Dekkers LL, Rozemuller AJ, Korth C, M\u00fcller-Schiffmann A, et al. BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer\u2019s disease. Neurobiol Aging. 2014;35:1596\u2013604.","journal-title":"Neurobiol Aging"},{"key":"3161_CR20","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-131364","volume":"40","author":"M Del Campo","year":"2014","unstructured":"Del Campo M, Teunissen CE. Role of BRI2 in dementia. J Alzheimers Dis. 2014;40:481\u201394.","journal-title":"J Alzheimers Dis"},{"key":"3161_CR21","first-page":"659","volume":"7","author":"E Hermansson","year":"2014","unstructured":"Hermansson E, Schultz S, Crowther D, Linse S, Winblad B, Westermark G, et al. The chaperone domain BRICHOS prevents CNS toxicity of amyloid-beta peptide in Drosophila melanogaster. Dis Model Mech. 2014;7:659\u201365.","journal-title":"Dis Model Mech"},{"key":"3161_CR22","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1042\/BCJ20160277","volume":"473","author":"H Poska","year":"2016","unstructured":"Poska H, Haslbeck M, Kurudenkandy FR, Hermansson E, Chen G, Kostallas G, et al. Dementia-related Bri2 BRICHOS is a versatile molecular chaperone that efficiently inhibits A\u03b242 toxicity in Drosophila. Biochemical Journal. 2016;473:3683\u2013704.","journal-title":"Biochemical Journal"},{"key":"3161_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3233\/ADR-170051","volume":"2","author":"L Dolfe","year":"2018","unstructured":"Dolfe L, Tambaro S, Tigro H, Del Campo M, Hoozemans JJM, Wiehager B, et al. The Bri2 and Bri3 BRICHOS domains interact differently with abeta(42) and Alzheimer amyloid plaques. J Alzheimers Dis Rep. 2018;2:27\u201339.","journal-title":"J Alzheimers Dis Rep"},{"key":"3161_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.ymthe.2022.08.010","volume":"31","author":"S Manchanda","year":"2023","unstructured":"Manchanda S, Galan-Acosta L, Abelein A, Tambaro S, Chen G, Nilsson P, et al. Intravenous treatment with a molecular chaperone designed against beta-amyloid toxicity improves Alzheimer\u2019s disease pathology in mouse models. Mol Ther. 2023;31:487\u2013502.","journal-title":"Mol Ther"},{"key":"3161_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02056-4","volume":"8","author":"G Chen","year":"2017","unstructured":"Chen G, Abelein A, Nilsson HE, Leppert A, Andrade-Talavera Y, Tambaro S, et al. Bri2 BRICHOS client specificity and chaperone activity are governed by assembly state. Nat Commun. 2017;8:2081.","journal-title":"Nat Commun"},{"key":"3161_CR26","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1074\/jbc.RA118.004538","volume":"294","author":"S Tambaro","year":"2019","unstructured":"Tambaro S, Galan-Acosta L, Leppert A, Chen G, Biverstal H, Presto J, et al. Blood\u2013brain and blood-cerebrospinal fluid passage of BRICHOS domains from two molecular chaperones in mice. J Biol Chem. 2019;294:2606\u201315.","journal-title":"J Biol Chem"},{"key":"3161_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s42003-020-0757-z","volume":"3","author":"G Chen","year":"2020","unstructured":"Chen G, Andrade-Talavera Y, Tambaro S, Leppert A, Nilsson HE, Zhong X, et al. Augmentation of Bri2 molecular chaperone activity against amyloid-beta reduces neurotoxicity in mouse hippocampus in vitro. Commun Biol. 2020;3:32.","journal-title":"Commun Biol"},{"key":"3161_CR28","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nn.3697","volume":"17","author":"T Saito","year":"2014","unstructured":"Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, et al. Single App knock-in mouse models of Alzheimer\u2019s disease. Nat Neurosci. 2014;17:661\u20133.","journal-title":"Nat Neurosci"},{"key":"3161_CR29","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.15252\/embj.201797397","volume":"36","author":"H Sasaguri","year":"2017","unstructured":"Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, et al. APP mouse models for Alzheimer\u2019s disease preclinical studies. EMBO J. 2017;36:2473\u201387.","journal-title":"EMBO J"},{"key":"3161_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/nsmb.2971","volume":"22","author":"SIA Cohen","year":"2015","unstructured":"Cohen SIA, Arosio P, Presto J, Kurudenkandy FR, Biverst\u00e5l H, Dolfe L, et al. A molecular chaperone breaks the catalytic cycle that generates toxic A\u03b2 oligomers. Nature Structural & Molecular Biology. 2015;22:207\u201313.","journal-title":"Nature Structural & Molecular Biology"},{"key":"3161_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45192-4","volume":"15","author":"R Kumar","year":"2024","unstructured":"Kumar R, Le Marchand T, Adam L, Bobrovs R, Chen G, Fridmanis J, et al. Identification of potential aggregation hotspots on Abeta42 fibrils blocked by the anti-amyloid chaperone-like BRICHOS domain. Nat Commun. 2024;15:965.","journal-title":"Nat Commun"},{"key":"3161_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcn.2020.103498","volume":"105","author":"L Galan-Acosta","year":"2020","unstructured":"Galan-Acosta L, Sierra C, Leppert A, Pouliopoulos AN, Kwon N, Noel RL, et al. Recombinant BRICHOS chaperone domains delivered to mouse brain parenchyma by focused ultrasound and microbubbles are internalized by hippocampal and cortical neurons. Mol Cell Neurosci. 2020;105:103498.","journal-title":"Mol Cell Neurosci"},{"key":"3161_CR33","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.cell.2020.06.038","volume":"182","author":"WT Chen","year":"2020","unstructured":"Chen WT, Lu A, Craessaerts K, Pavie B, Sala Frigerio C, Corthout N, et al. Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer\u2019s Disease. Cell. 2020;182:976\u201391.e919.","journal-title":"Cell"},{"key":"3161_CR34","doi-asserted-by":"crossref","unstructured":"Gedam M, Comerota MM, Propson NE, Chen T, Jin F, Wang MC, et al. Complement C3aR depletion reverses HIF-1alpha-induced metabolic impairment and enhances microglial response to Abeta pathology. J Clin Invest. 2023;133:e167501.","DOI":"10.1172\/JCI167501"},{"key":"3161_CR35","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.celrep.2019.03.099","volume":"27","author":"C Sala Frigerio","year":"2019","unstructured":"Sala Frigerio C, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, et al. The major risk factors for Alzheimer\u2019s disease: age, sex, and genes modulate the microglia response to abeta plaques. Cell Rep. 2019;27:1293\u2013306.e1296.","journal-title":"Cell Rep"},{"key":"3161_CR36","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3161_CR37","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45:D353\u2013D361.","journal-title":"Nucleic Acids Res"},{"key":"3161_CR38","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1039\/D3MD00040K","volume":"14","author":"A Abelein","year":"2023","unstructured":"Abelein A, Johansson J. Amyloid inhibition by molecular chaperones in vitro can be translated to Alzheimer\u2019s pathology in vivo. RSC Med Chem. 2023;14:848\u201357.","journal-title":"RSC Med Chem"},{"key":"3161_CR39","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.4103\/NRR.NRR-D-23-01927","volume":"19","author":"G Chen","year":"2024","unstructured":"Chen G, Johansson J. Potential of molecular chaperones for treating Alzheimer\u2019s disease. Neural Regeneration Research. 2024;19:2343\u20134.","journal-title":"Neural Regeneration Research"},{"key":"3161_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202250083","volume":"53","author":"I Badolati","year":"2023","unstructured":"Badolati I, van der Heiden M, Brodin D, Zuurveld M, Szilagyi S, Bjorkander S, et al. Staphylococcus aureus-derived factors promote human Th9 cell polarization and enhance a transcriptional program associated with allergic inflammation. Eur J Immunol. 2023;53:e2250083.","journal-title":"Eur J Immunol"},{"key":"3161_CR41","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169:1276\u201390.e1217.","journal-title":"Cell"},{"key":"3161_CR42","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chetelat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397:1577\u201390.","journal-title":"Lancet"},{"key":"3161_CR43","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s44321-024-00041-1","volume":"16","author":"J Johansson","year":"2024","unstructured":"Johansson J. Treatment with BRICHOS domain helps to clarify issues with Alzheimer mouse models. EMBO Mol Med. 2024;16:715\u20136.","journal-title":"EMBO Mol Med"},{"key":"3161_CR44","first-page":"1005","volume":"12","author":"T Wyss-Coray","year":"2006","unstructured":"Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005\u201315.","journal-title":"Nat Med"},{"key":"3161_CR45","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3109\/00207454.2013.833510","volume":"124","author":"Z Cai","year":"2014","unstructured":"Cai Z, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer\u2019s disease. Int J Neurosci. 2014;124:307\u201321.","journal-title":"Int J Neurosci"},{"key":"3161_CR46","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.pneurobio.2016.01.001","volume":"144","author":"LM Osborn","year":"2016","unstructured":"Osborn LM, Kamphuis W, Wadman WJ, Hol EM. Astrogliosis: an integral player in the pathogenesis of Alzheimer\u2019s disease. Prog Neurobiol. 2016;144:121\u201341.","journal-title":"Prog Neurobiol"},{"key":"3161_CR47","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11307-017-1153-z","volume":"20","author":"M Olsen","year":"2018","unstructured":"Olsen M, Aguilar X, Sehlin D, Fang XT, Antoni G, Erlandsson A, et al. Astroglial responses to amyloid-beta progression in a mouse model of Alzheimer\u2019s disease. Mol Imaging Biol. 2018;20:605\u201314.","journal-title":"Mol Imaging Biol"},{"key":"3161_CR48","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/0166-2236(96)10049-7","volume":"19","author":"GW Kreutzberg","year":"1996","unstructured":"Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19:312\u20138.","journal-title":"Trends Neurosci"},{"key":"3161_CR49","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/nn1997","volume":"10","author":"UK Hanisch","year":"2007","unstructured":"Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007;10:1387\u201394.","journal-title":"Nat Neurosci"},{"key":"3161_CR50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13024-017-0184-x","volume":"12","author":"AG Efthymiou","year":"2017","unstructured":"Efthymiou AG, Goate AM. Late onset Alzheimer\u2019s disease genetics implicates microglial pathways in disease risk. Mol Neurodegener. 2017;12:43.","journal-title":"Mol Neurodegener"},{"key":"3161_CR51","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40478-021-01216-4","volume":"9","author":"C Emre","year":"2021","unstructured":"Emre C, Do KV, Jun B, Hjorth E, Alcalde SG, Kautzmann MI, et al. Age-related changes in brain phospholipids and bioactive lipids in the APP knock-in mouse model of Alzheimer\u2019s disease. Acta Neuropathol Commun. 2021;9:116.","journal-title":"Acta Neuropathol Commun"},{"key":"3161_CR52","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/ng.440","volume":"41","author":"D Harold","year":"2009","unstructured":"Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease. Nat Genet. 2009;41:1088\u201393.","journal-title":"Nat Genet"},{"key":"3161_CR53","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"JC Lambert","year":"2009","unstructured":"Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease. Nat Genet. 2009;41:1094\u20139.","journal-title":"Nat Genet"},{"key":"3161_CR54","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1042\/bj2930027","volume":"293","author":"J Ghiso","year":"1993","unstructured":"Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T, et al. The cerebrospinal-fluid soluble form of Alzheimer\u2019s amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J. 1993;293:27\u201330.","journal-title":"Biochem J"},{"key":"3161_CR55","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1042\/bj3160671","volume":"316","author":"E Matsubara","year":"1996","unstructured":"Matsubara E, Soto C, Governale S, Frangione B, Ghiso J. Apolipoprotein J and Alzheimer\u2019s amyloid beta solubility. Biochem J. 1996;316:671\u20139.","journal-title":"Biochem J"},{"key":"3161_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/nsmb.2191","volume":"19","author":"P Narayan","year":"2011","unstructured":"Narayan P, Orte A, Clarke RW, Bolognesi B, Hook S, Ganzinger KA, et al. The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-beta(1\u201340) peptide. Nat Struct Mol Biol. 2011;19:79\u201383.","journal-title":"Nat Struct Mol Biol"},{"key":"3161_CR57","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1046\/j.1471-4159.1996.67031324.x","volume":"67","author":"LN Boggs","year":"1996","unstructured":"Boggs LN, Fuson KS, Baez M, Churgay L, McClure D, Becker G, et al. Clusterin (Apo J) protects against in vitro amyloid-beta (1\u201340) neurotoxicity. J Neurochem. 1996;67:1324\u20137.","journal-title":"J Neurochem"},{"key":"3161_CR58","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1017\/S0317167100029796","volume":"16","author":"PC May","year":"1989","unstructured":"May PC, Johnson SA, Poirier J, Lampert-Etchells M, Finch CE. Altered gene expression in Alzheimer\u2019s disease brain tissue. Can J Neurol Sci. 1989;16:473\u20136.","journal-title":"Can J Neurol Sci"},{"key":"3161_CR59","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1001\/jama.2011.381","volume":"305","author":"SchrijversEM Koudstaal","year":"2011","unstructured":"Koudstaal SchrijversEM, Hofman PJ, Breteler AMM. Plasma clusterin and the risk of Alzheimer disease. JAMA. 2011;305:1322\u20136.","journal-title":"JAMA"},{"key":"3161_CR60","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3233\/JAD-2011-110251","volume":"25","author":"B Schurmann","year":"2011","unstructured":"Schurmann B, Wiese B, Bickel H, Weyerer S, Riedel-Heller SG, Pentzek M, et al. Association of the Alzheimer\u2019s disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis. 2011;25:421\u20134.","journal-title":"J Alzheimers Dis"},{"key":"3161_CR61","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/archgenpsychiatry.2010.78","volume":"67","author":"M Thambisetty","year":"2010","unstructured":"Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010;67:739\u201348.","journal-title":"Arch Gen Psychiatry"},{"key":"3161_CR62","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL, Mila-Aloma M, Vrillon A, Ashton NJ, Pascoal TA, Lussier F, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78:1471\u201383.","journal-title":"JAMA Neurol"},{"key":"3161_CR63","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/nan.12338","volume":"43","author":"CJ Garwood","year":"2017","unstructured":"Garwood CJ, Ratcliffe LE, Simpson JE, Heath PR, Ince PG, Wharton SB. Review: astrocytes in Alzheimer\u2019s disease and other age-associated dementias: a supporting player with a central role. Neuropathol Appl Neurobiol. 2017;43:281\u201398.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"3161_CR64","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13195-020-00682-7","volume":"12","author":"IMW Verberk","year":"2020","unstructured":"Verberk IMW, Thijssen E, Koelewijn J, Mauroo K, Vanbrabant J, de Wilde A, et al. Combination of plasma amyloid beta((1\u201342\/1\u201340)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12:118.","journal-title":"Alzheimers Res Ther"},{"key":"3161_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-020-01137-1","volume":"11","author":"P Chatterjee","year":"2021","unstructured":"Chatterjee P, Pedrini S, Stoops E, Goozee K, Villemagne VL, Asih PR, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease. Transl Psychiatry. 2021;11:27.","journal-title":"Transl Psychiatry"},{"key":"3161_CR66","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/alz.12283","volume":"17","author":"J Simren","year":"2021","unstructured":"Simren J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2021;17:1145\u201356.","journal-title":"Alzheimers Dement"},{"key":"3161_CR67","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jalz.2019.09.004","volume":"16","author":"FM Elahi","year":"2020","unstructured":"Elahi FM, Casaletto KB, La Joie R, Walters SM, Harvey D, Wolf A, et al. Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer\u2019s disease. Alzheimers Dement. 2020;16:681\u201395.","journal-title":"Alzheimers Dement"},{"key":"3161_CR68","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3233\/JAD-180325","volume":"67","author":"P Oeckl","year":"2019","unstructured":"Oeckl P, Halbgebauer S, Anderl-Straub S, Steinacker P, Huss AM, Neugebauer H, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer\u2019s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67:481\u20138.","journal-title":"J Alzheimers Dis"},{"key":"3161_CR69","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13195-021-00804-9","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, et al. Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimers Res Ther. 2021;13:68.","journal-title":"Alzheimers Res Ther"},{"key":"3161_CR70","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3233\/JAD-200755","volume":"78","author":"BM Asken","year":"2020","unstructured":"Asken BM, Elahi FM, La Joie R, Strom A, Staffaroni AM, Lindbergh CA, et al. Plasma glial fibrillary acidic protein levels differ along the spectra of amyloid burden and clinical disease stage. J Alzheimers Dis. 2020;78:265\u201376.","journal-title":"J Alzheimers Dis"},{"key":"3161_CR71","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3233\/JAD-141902","volume":"44","author":"C Barucker","year":"2015","unstructured":"Barucker C, Sommer A, Beckmann G, Eravci M, Harmeier A, Schipke CG, et al. Alzheimer amyloid peptide abeta42 regulates gene expression of transcription and growth factors. J Alzheimers Dis. 2015;44:613\u201324.","journal-title":"J Alzheimers Dis"},{"key":"3161_CR72","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/biof.5520330202","volume":"33","author":"Z Salehi","year":"2008","unstructured":"Salehi Z, Mashayekhi F, Naji M. Insulin like growth factor-1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer\u2019s disease. Biofactors. 2008;33:99\u2013106.","journal-title":"Biofactors"},{"key":"3161_CR73","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.cell.2009.11.014","volume":"139","author":"E Cohen","year":"2009","unstructured":"Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, et al. Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell. 2009;139:1157\u201369.","journal-title":"Cell"},{"key":"3161_CR74","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1096\/fj.09-132043","volume":"23","author":"S Freude","year":"2009","unstructured":"Freude S, Hettich MM, Schumann C, Stohr O, Koch L, Kohler C, et al. Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer\u2019s disease. FASEB J. 2009;23:3315\u201324.","journal-title":"FASEB J"},{"key":"3161_CR75","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40478-022-01352-5","volume":"10","author":"S Rauskolb","year":"2022","unstructured":"Rauskolb S, Andreska T, Fries S, von Collenberg CR, Blum R, Monoranu CM, et al. Insulin-like growth factor 5 associates with human Ass plaques and promotes cognitive impairment. Acta Neuropathol Commun. 2022;10:68.","journal-title":"Acta Neuropathol Commun"},{"key":"3161_CR76","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s00401-008-0373-3","volume":"115","author":"JH Power","year":"2008","unstructured":"Power JH, Asad S, Chataway TK, Chegini F, Manavis J, Temlett JA, et al. Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer\u2019s disease pathology. Acta Neuropathol. 2008;115:611\u201322.","journal-title":"Acta Neuropathol"},{"key":"3161_CR77","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13024-020-00401-8","volume":"15","author":"JE Pankiewicz","year":"2020","unstructured":"Pankiewicz JE, Diaz JR, Marta-Ariza M, Lizinczyk AM, Franco LA, Sadowski MJ. Peroxiredoxin 6 mediates protective function of astrocytes in Abeta proteostasis. Mol Neurodegener. 2020;15:50.","journal-title":"Mol Neurodegener"},{"key":"3161_CR78","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566\u201381.e569.","journal-title":"Immunity"},{"key":"3161_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23762-0","volume":"12","author":"NF Fitz","year":"2021","unstructured":"Fitz NF, Nam KN, Wolfe CM, Letronne F, Playso BE, Iordanova BE, et al. Phospholipids of APOE lipoproteins activate microglia in an isoform-specific manner in preclinical models of Alzheimer\u2019s disease. Nat Commun. 2021;12:3416.","journal-title":"Nat Commun"},{"key":"3161_CR80","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/s44319-024-00077-x","volume":"25","author":"T Yin","year":"2024","unstructured":"Yin T, Yesiltepe M, D\u2019Adamio L. Functional BRI2-TREM2 interactions in microglia: implications for Alzheimer\u2019s and related dementias. EMBO Rep. 2024;25:1326\u201360.","journal-title":"EMBO Rep"},{"key":"3161_CR81","doi-asserted-by":"publisher","first-page":"101165","DOI":"10.1016\/j.plipres.2022.101165","volume":"86","author":"SC Dyall","year":"2022","unstructured":"Dyall SC, Balas L, Bazan NG, Brenna JT, Chiang N, da Costa, et al. Polyunsaturated fatty acids and fatty acid-derived lipid mediators: Recent advances in the understanding of their biosynthesis, structures, and functions. Prog Lipid Res. 2022;86:101165.","journal-title":"Prog Lipid Res"},{"key":"3161_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107879","volume":"227","author":"D Panigrahy","year":"2021","unstructured":"Panigrahy D, Gilligan MM, Serhan CN, Kashfi K. Resolution of inflammation: an organizing principle in biology and medicine. Pharmacol Ther. 2021;227:107879.","journal-title":"Pharmacol Ther"},{"key":"3161_CR83","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 2015;14:388\u2013405.","journal-title":"Lancet Neurol"},{"key":"3161_CR84","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016;388:505\u201317.","journal-title":"Lancet"},{"key":"3161_CR85","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1007\/s10571-022-01216-5","volume":"43","author":"KV Do","year":"2023","unstructured":"Do KV, Hjorth E, Wang Y, Jun B, Kautzmann MI, Ohshima M, et al. Cerebrospinal fluid profile of lipid mediators in Alzheimer\u2019s disease. Cell Mol Neurobiol. 2023;43:797\u2013811.","journal-title":"Cell Mol Neurobiol"},{"key":"3161_CR86","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bpa.12812","volume":"30","author":"C Emre","year":"2020","unstructured":"Emre C, Hjorth E, Bharani K, Carroll S, Granholm AC, Schultzberg M. Receptors for pro-resolving mediators are increased in Alzheimer\u2019s disease brain. Brain Pathol. 2020;30:614\u201340.","journal-title":"Brain Pathol"},{"key":"3161_CR87","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1172\/JCI25420","volume":"115","author":"WJ Lukiw","year":"2005","unstructured":"Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest. 2005;115:2774\u201383.","journal-title":"J Clin Invest"},{"key":"3161_CR88","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jalz.2013.12.024","volume":"11","author":"X Wang","year":"2015","unstructured":"Wang X, Zhu M, Hjorth E, Cort\u00e9s-Toro V, Eyjolfsdottir H, Graff C, et al. Resolution of inflammation is altered in Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2015;11:40\u201350.","journal-title":"Alzheimer\u2019s & Dementia"},{"key":"3161_CR89","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1007\/s12035-015-9544-0","volume":"53","author":"M Zhu","year":"2016","unstructured":"Zhu M, Wang X, Hjorth E, Colas RA, Schroeder L, Granholm AC, et al. Pro-resolving lipid mediators improve neuronal survival and increase A\u03b242 phagocytosis. Mol Neurobiol. 2016;53:2733\u201349.","journal-title":"Mol Neurobiol"},{"key":"3161_CR90","doi-asserted-by":"publisher","DOI":"10.1002\/cpns.71","volume":"88","author":"LM Holt","year":"2019","unstructured":"Holt LM, Stoyanof ST, Olsen ML. Magnetic cell sorting for in vivo and in vitro astrocyte, neuron, and microglia analysis. Curr Protoc Neurosci. 2019;88:e71.","journal-title":"Curr Protoc Neurosci"},{"key":"3161_CR91","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739\u201340.","journal-title":"Bioinformatics"},{"key":"3161_CR92","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325.","journal-title":"Cell Syst"},{"key":"3161_CR93","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583\u20139.","journal-title":"Nature"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03161-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03161-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03161-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T15:02:36Z","timestamp":1729782156000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-024-03161-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,24]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3161"],"URL":"https:\/\/doi.org\/10.1038\/s41398-024-03161-x","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,24]]},"assertion":[{"value":"30 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Procedures for handling and conducting animal experiments were carried out in compliance with the comparative medicine guidelines (KM-B, Karolinska Institutet, Sweden) and the experiments were approved by the Stockholm Ethical Committee for Animal Experiments (15949-2020). No human participants were included in any of the studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"453"}}